Overcoming resistance to tyrosine kinase inhibitors in lung cancer
克服肺癌对酪氨酸激酶抑制剂的耐药性
基本信息
- 批准号:9231401
- 负责人:
- 金额:--
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2013
- 资助国家:美国
- 起止时间:2013-03-06 至 2019-02-28
- 项目状态:已结题
- 来源:
- 关键词:Amino AcidsBindingCancer EtiologyCancer cell lineCellsCessation of lifeClinicalClinical ResearchComplexDevelopmentDiagnostic radiologic examinationDissociationE-CadherinEGF geneEffectivenessEpidermal Growth Factor ReceptorErlotinibFutureGatekeepingGefitinibGenesGoalsGrowthGrowth FactorHumanLeadLung NeoplasmsMalignant NeoplasmsMalignant neoplasm of lungMediatingMethionineModelingMusMutationNon-Small-Cell Lung CarcinomaNuclear TranslocationOncogenicPathway interactionsPatient CarePatientsPlayPositioning AttributeProto-Oncogene Proteins c-aktReporterResistanceRoleSignal TransductionSomatic MutationTestingThreonineTransgenic MiceTransplantationTyrosine Kinase DomainTyrosine Kinase InhibitorTyrosine PhosphorylationUnited StatesWorkalpha cateninbasebeta catenincancer cellcancer therapychemotherapyexperimental studyglycogen synthase kinase 3 betain vivoinhibitor/antagonistinnovationinsightlung tumorigenesismouse modelmutantnovelnovel strategiesnovel therapeutic interventionnovel therapeuticspersonalized medicinepreventpublic health relevancereceptorresponsesmall moleculestandard caretargeted treatmenttumortumor growthtumor initiationtumorigenesis
项目摘要
DESCRIPTION (provided by applicant): The discovery of somatic mutations in epidermal growth receptor (EGFR) in patients who show dramatic response to reversible EGFR tyrosine kinase inhibitors (TKIs) gefitinib or erlotinib has introduced the concept of "personalized therapy in lung cancer treatment. However, resistance to the inhibitors emerges within one to two years. The secondary EGFR-T790M mutation, in the "gate-keeper" position of the tyrosine kinase domain, is present in more than 50% of lung cancers with acquired resistance to gefitinib or erlotinib. Since treatment options for these patients are currently limited, novel strategies to prevent or overcome acquired resistance to EGFR TKIs are sorely needed. We have demonstrated that ß-catenin is upregulated and activated in lung cancer cells harboring EGFR mutations including EGFR-T790M. As aberrant activation of ß-catenin signaling can lead to human cancers, we hypothesize that ß-catenin plays an essential role in lung tumorigenesis caused by EGFR mutants and inhibiting its activation alone or in combination with irreversible EGFR inhibitors may be an alternative strategy to overcome resistance to gefitinib or erlotinib. Therefore, our specific aims are to: (1) Investigate the mechanisms by which EGFR mutants lead to accumulation, nuclear translocation, and activation of �-catenin; (2) Investigate whether activation of ß-catenin is required for EGFR- T790M-driven lung cancer formation/progression in vivo; and (3) Evaluate the effectiveness of ß-catenin inhibition as a novel therapeutic strategy to
overcome resistance to erlotinib or gefitinib. We believe that the experiments proposed here will provide novel insights into the detailed mechanisms by which EGFR mutations cause tumorigenesis and innovative approaches to overcome resistance to gefitinib or erlotinib, significantly impacting care of patients with lung cancer in the near future.
描述(适用提供):在表皮生长受体(EGFR)中发现对可逆的EGFR EGFR酪氨酸激酶抑制剂(TKIS)Gefitinib或Erlotinib的剧烈反应的患者发现了体细胞突变。但是,在肺癌治疗中,“抗癌症”的概念是在肺癌中的7年中介绍了一个syne-necrions news in news in news in newne newne news in newne news news newne news in news in unipers in nection。在酪氨酸激酶结构域的“守门员”位置中,在超过50%的肺癌中存在对吉非替尼或厄洛替尼的耐药性,因为这些患者的治疗方案目前是有限的,可预防或克服对EGFR TKIS的抗性的新颖策略。 EGFR-T790M导致人类癌症,我们假设β-catenin在由EGFR突变体引起的肺肿瘤发生中起着至关重要的作用,并且仅抑制其激活或与不可逆的EGFR抑制剂结合使用,这可能是胜过gefitinib抗抑郁症的替代策略。因此,我们的具体目的是:(1)研究EGFR突变体导致累积,核易位和钙蛋白激活的机制; (2)研究EGFR-T790M驱动的肺癌形成/体内进展是否需要β-catenin的激活; (3)评估β-catenin抑制作用作为一种新型治疗策略的有效性
克服对厄洛替尼或吉非替尼的抗性。我们认为,此处提出的实验将提供有关EGFR突变引起肿瘤发生和创新方法的详细机制的新见解,以克服对Gefitinib或Erlotinib的抵抗力,从而在不久的将来对肺癌患者的护理产生显着影响。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Susumu Kobayashi其他文献
Susumu Kobayashi的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Susumu Kobayashi', 18)}}的其他基金
Overcoming resistance to tyrosine kinase inhibitors in lung cancer
克服肺癌对酪氨酸激酶抑制剂的耐药性
- 批准号:
8819035 - 财政年份:2013
- 资助金额:
-- - 项目类别:
Overcoming resistance to tyrosine kinase inhibitors in lung cancer
克服肺癌对酪氨酸激酶抑制剂的耐药性
- 批准号:
8502958 - 财政年份:2013
- 资助金额:
-- - 项目类别:
Overcoming resistance to tyrosine kinase inhibitors in lung cancer
克服肺癌对酪氨酸激酶抑制剂的耐药性
- 批准号:
8633020 - 财政年份:2013
- 资助金额:
-- - 项目类别:
Role of EGFR mutations and new therapeutics in lung cancer
EGFR 突变和新疗法在肺癌中的作用
- 批准号:
7940258 - 财政年份:2009
- 资助金额:
-- - 项目类别:
Role of EGFR mutations and new therapeutics in lung cancer
EGFR 突变和新疗法在肺癌中的作用
- 批准号:
7455166 - 财政年份:2007
- 资助金额:
-- - 项目类别:
Role of EGFR mutations and new therapeutics in lung cancer
EGFR 突变和新疗法在肺癌中的作用
- 批准号:
8115164 - 财政年份:2007
- 资助金额:
-- - 项目类别:
相似国自然基金
结合态抗生素在水产品加工过程中的消解机制与产物毒性解析
- 批准号:32302247
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
ABHD6与AMPA受体结合位点的鉴定及该位点在AMPA受体转运和功能调控中的作用研究
- 批准号:32300794
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
α-突触核蛋白与脂肪酸结合蛋白FABP3相互作用维持自身低聚体形态的机制研究
- 批准号:82301632
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
基于荧光共振能量转移机理构建多肽荧光探针用于可视化Zn2+结合SQSTM1/p62调节自噬在前列腺癌去势耐受中的作用机制
- 批准号:82303568
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
手性氢键供体与阴离子结合催化乙烯基醚的立体选择性阳离子聚合
- 批准号:22301279
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
Coordination of DNA Metabolism by Replication Protein A
复制蛋白 A 协调 DNA 代谢
- 批准号:
10623523 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Evaluation of a therapeutic vaccination strategy with motif neoepitope peptide-pulsed autologous dendritic cells for non-small cell lung cancer patients harboring a charged HLA-B binding pocket.
使用基序新表位肽脉冲的自体树突状细胞对携带带电 HLA-B 结合袋的非小细胞肺癌患者的治疗性疫苗接种策略进行评估。
- 批准号:
10721983 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Development of drug conjugates of R-spondin peptibodies for the treatment of colorectal cancer
开发用于治疗结直肠癌的 R-spondin 肽体药物缀合物
- 批准号:
10696733 - 财政年份:2023
- 资助金额:
-- - 项目类别:
RLIP, Mitochondrial Dysfunction in Alzheimer’s Disease
RLIP,阿尔茨海默病中的线粒体功能障碍
- 批准号:
10901025 - 财政年份:2023
- 资助金额:
-- - 项目类别:
HLA B44 motif neoepitopes in NSCLC: Evaluating their effects on the TME and adding them to established markers in a model to predict durable benefit from PD- 1 inhibition with and without chemotherapy
NSCLC 中的 HLA B44 基序新表位:评估它们对 TME 的影响,并将它们添加到模型中已建立的标记中,以预测有或没有化疗的 PD-1 抑制的持久益处
- 批准号:
10681851 - 财政年份:2023
- 资助金额:
-- - 项目类别: